Ameriprise’s Cellectis CLLS Stock Holding History

Ameriprise’s Portfolio CLLS Stock Details CLLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-11,822	Closed	-$184K	–	3873
2021 Q2	$184K	Buy	+11,822	New	+$199K	﹤0.01%	3771

Other funds holding CLLS

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

CII

Capital International Inc Los Angeles, California $13B AUM 31.88% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Bpifrance Maisons Alfort, Cedex, France $1.65B AUM 19.85% 1-Year Est. Return

Ameriprise's CLLS Position: Q3 2021 in Review

Ameriprise sold out of Cellectis (CLLS) in Q3 2021, closing a stake of 11,822 shares — an estimated $184K sold.

Ameriprise first reported a position in CLLS in Q2 2021 and held it in 1 quarter. The position peaked at $184K in Q2 2021. 70 funds tracked by Wall St. Rank hold CLLS as of Q3 2021.

Ameriprise reported no remaining Cellectis position as of Q3 2021 after selling out during the quarter.
Ameriprise sold 11,822 Cellectis shares in Q3 2021, an estimated $184K.
Ameriprise first reported a position in Cellectis in Q2 2021 and held it in 1 quarter.
Ameriprise's Cellectis position peaked at $184K in Q2 2021.
70 funds tracked by Wall St. Rank held Cellectis as of Q3 2021.

Based on Ameriprise's 13F filing for Q3 2021, filed 15 Nov 2021.